Abstract
We assessed the in vitro antibacterial activity against clinical isolates, clinical efficacy and safety of ceftazidime (CAZ, SN401), a new cephem antibiotic developed by Glaxo in the UK, and obtained the following resutls.
1. Susceptibility of clinical isolates to CAZ: With the inoclum size of 106 CFU/ml, the peak distribution of MICs of CAZ was found at 12.5 μg/nil for S. aureus, 0.2 μg/ml for E. coli, 0.2μg/ml for K. pneumoniae, 0.025μg/ml or below for P. mirabilis and P. vulgaris, and 1.56μg/ml for P. aeruginosa. The antibacterial activity of CAZ against Proteus sp. and P. aeruginosa was affected by inoculum size, and with 108 CFU/ml, the activity of CAZ was reduced. 2. CAZ was administered at a daily dose of 2 g to a total of 10 patients: 1 with septicemia, 2 with pneumonia, 1 with lung abscess, 3 with infected to lung cancer, 1 with chronic obstructive pulmonary disease with infection, 1 with diffuse panbronchiolitis and 1 with pulmonary tuberculosis. The clinical results of the 9 cases excluding 1 case of pulmonary tuberculosis were evaluated as excellent in 2 cases, good in 4, fair in 2, and 1 as unassessable case.
In all cases, no side effect was noted.
